Can 'Supercharged' donor cells beat viruses that drugs Can't?
NCT ID NCT07662369
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure how many patients clear the virus or see at least a 50% reduction in viral load.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD45RA-depleted donor lymphocyte infusion (DLI)
- What this could lead to
- If it works, this could offer a new way to fight viral infections that don't respond to standard drugs after a stem cell transplant.
- What could go wrong
- This is an early phase 1/2 trial with only 30 participants, so results are preliminary. There may be risks like graft-versus-host disease or the treatment not working for all viruses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
RECRUITINGShanghai, SH, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can cord blood t cells be trained to stop viral infections after transplant?
- Frailty check may steer safer cancer care for seniors
- Can a new IV antiviral tame two stubborn viruses?
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?